Navigation Links
Drugs for Irritable Bowel Might Increase Cancer Risk

Long-term use of thiopurines bears further study, researchers say

MONDAY, Oct. 19 (HealthDay News) -- The use of thiopurine drugs to treat inflammatory bowel disease (IBD) increases the risk of cancers related to viral infection, according to a new study.

IBD includes Crohn's disease and ulcerative colitis. Thiopurine drugs are used to suppress the immune system in order to maintain remission in IBD patients.

For this study, French researchers analyzed data on 19,486 IBD patients (60 percent with Crohn's and 40 percent with ulcerative colitis or unclassified IBD) who were followed for a median of 35 months.

At the start of the study, 30 percent of patients were taking thiopurines, 14 percent had discontinued them, and 56 percent had never received thiopurines. During the study, 23 patients developed malignant lymphoproliferative disorders (LD) -- cancers that are associated with viral infection, particularly those linked to Epstein Barr virus (EBV) infection.

Of the 23 patients with LD, 22 had non-Hodgkin's lymphoma and one had Hodgkin's lymphoma. Incidence rates of LD were 0.90 per 1,000 patient-years in those receiving thiopurines, 0.20 per 1,000 patient-years in those who'd discontinued the drugs, and 0.26 per 1,000 patient-years in those who'd never taken thiopurines.

The researchers calculated that IBD patients taking thiopurines had a more-than-five-fold increased risk compared to those who'd never received the drugs. Older patients, men, and those who'd had IBD for longer were also at increased risk of LD.

"Extrapolating our results, the absolute cumulative risk of (LD) in young patients receiving a 10-year course of thiopurines remains low (less than 1 percent) and does not undermine the positive risk-benefit ratio of these drugs. For elderly patients and unlimited treatment periods, the question should be addressed in dedicated studies," wrote Laurent Beaugerie, a professor at Hospital Saint-Antoine, Paris, and colleagues.

The study appeared online Monday and in an upcoming print issue of The Lancet.

"Although we recognize the slightly increased risk of lymphoma, these agents will probably remain one of the cornerstones of treatment. Nonetheless, physicians should be cautious when prolonged combined and deep immunosuppression is needed to achieve disease control," Dr. Geert D'Haens, of the Imelda GI Clinical Research Centre and University Hospital Gasthuisberg in Belgium, and Dr. Paul Rutgeerts, University Hospital Gasthuisberg, wrote in an accompanying editorial.

More information

The Crohn's and Colitis Foundation of America has more about IBD.

-- Robert Preidt

SOURCE: The Lancet, news release, Oct. 18, 2009

Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Pitt researchers find candidates for new HIV drugs
2. Designing drugs and their antidotes together improves patient care
3. Risk of abnormally slow heart rate twice as high in those taking drugs to slow Alzheimers
4. Teen attitudes toward smoking linked to likelihood of drinking and using drugs
5. UCLA study identifies 2 chemicals that could lead to new drugs for genetic disorders
6. GENova Biotherapeutics secures new cancer drugs targets
7. Reportlinker Adds World Anti-Obesity Drugs Market Report
8. Yeast unravels effects of chemotherapy drugs
9. Vitro's Cancer Stem Cell Therapy Complements New Hedge Hog Drugs
10. Antiviral Drugs Should Be Used Cautiously to Fight Flu, U.S. Says
11. Reportlinker Adds Prescription Drugs Report
Post Your Comments:
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... , June 24, 2016 ... of the "Structural Electronics 2015-2025: Applications, Technologies, ... In-Mold Electronics, Smart Skin, ... Photovoltaics Structural electronics involves electronic ... load-bearing, protective structures, replacing dumb structures such as ...
Breaking Medicine Technology: